Table 1.
Clinicopathological characteristics of recurrent and non-recurrent endometrial carcinoma in training and test group
| Characteristics | Training group (n = 104) | P value | Test group (n = 70) | P value | P value | ||
|---|---|---|---|---|---|---|---|
| No recurrence (n = 88) |
Recurrence (n = 16) |
No recurrence (n = 59) |
Recurrence (n = 11) |
||||
| Age at diagnosis (yr) | 55.0 ± 9.2 | 59.6 ± 13.7 | 0.035 | 56.6 ± 7.2 | 60.9 ± 7.9 | 0.280 | 0.154 |
| FIGO stage | < 0.001 | 0.006 | 0.026 | ||||
| IA | 44(50.0%) | 4(25.0%) | 44(74.6%) | 5(45.4%) | |||
| IB | 12(13.6%) | 2(12.5%) | 3(5.1%) | 2(18.2%) | |||
| II | 18(20.5%) | 1(6.2%) | 11(18.6%) | 1(9.1%) | |||
| IIIA | 4(4.5%) | 3(18.8%) | 0(0.0%) | 1(9.1%) | |||
| IIIC1 | 7(8.0%) | 2(12.5%) | 0(0.0%) | 1(9.1%) | |||
| IIIC2 | 3(3.4%) | 1(6.2%) | 1(1.7%) | 1(9.1%) | |||
| IVA | 0(0.0%) | 3(18.8%) | 0(0.0%) | 0(0.0%) | |||
| Tumor size (cm) | 0.035 | 0.750 | 0.442 | ||||
| < 3.5 | 42(47.7%) | 5(31.3%) | 31(52.5%) | 5(45.5%) | |||
| ≥3.5 | 46(52.3%) | 11(68.7%) | 28(47.5%) | 6(54.5%) | |||
| Pathological types | 0.078 | < 0.001 | 0.454 | ||||
| Endometrioid carcinoma | 74(84.1%) | 10(62.5%) | 50(84.7%) | 3(27.3%) | |||
| Non-endometrioid carcinoma | 14(15.9%) | 6(37.5%) | 9(15.3%) | 8(72.7%) | |||
| Myometrial invasion | 0.001 | 0.135 | 0.730 | ||||
| < 50% | 68(77.3%) | 6(37.5%) | 46(78.0%) | 6(54.5%) | |||
| ≥50% | 20(22.7%) | 10((62.5%) | 13(22.0%) | 5(45.5%) | |||
| LVSI | 0.001 | 0.143 | 0.305 | ||||
| Absent | 76(86.4%) | 8(50.0%) | 53(89.8%) | 8(72.7%) | |||
| Present | 12(13.6%) | 8(50.0%) | 6(10.2%) | 3(27.3%) | |||
| LNM | 0.410 | 0.062 | 0.106 | ||||
| Absent | 78(88.6%) | 13(81.3%) | 58(98.3%) | 9(81.8%) | |||
| Present | 10(11.4%) | 3(18.7%) | 1(1.7%) | 2(18.2%) | |||
| Ki-67 | 1.00 | 0.515 | 0.878 | ||||
| < 50% | 44(50.0%) | 8(50.0%) | 30(50.9%) | 4(36.4%) | |||
| ≥50% | 44(50.0%) | 8(50.0%) | 29(49.1%) | 7(63.6%) | |||
LVSI lymphovascular space invasion, LNM lymph node metastasis